surpass cvot tirzepatide SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I SURPASS-CVOT Published: Large Trial Confirms
Pay in 4 interest-free payments of $5.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Live Spec
SURPASS CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide SURPASS CVOT: Tirzepatide better than dulagluti MIMS SG Flow of Participants in the SURPASS 6 Trial See Table 3 for the details Download Scientific Diagram Overview of the SURPASS clinical trial program with tirzepatide in the Download Scientific Diagram Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASSCVOT design and baseline characteristics ScienceDirect
Store: selfdriverentaluganda.com · Domain: selfdriverentaluganda.com





















